---
figid: PMC2963106__nihms238832f2
figlink: /pmc/articles/PMC2963106/figure/F2/
number: Figure 2
caption: Binding of the HIFα–HIFβ heterodimer to the HRE in the promoter region results
  in transcriptional upregulation of genes important to the cell’s response to hypoxia.
  These include vascular endothelial growth factor (VEGF), platelet-derived growth
  factor (PDGF), transforming growth factor alpha (TGFα), carbonic anhydrase IX (CA-IX),
  erythropoietin (EPO), glucose transporter 1 (GLUT-1), and BCL2/adenovirus E1B 19
  kDa-interacting protein 3 (BNIP3). Binding of ligands, such as VEGF, to their respective
  cell surface receptors, such as VEGFR, leads to tyrosine phosphorylation of the
  receptor and subsequent downstream signaling through several kinase-dependent pathways,
  such as the PI3K–Akt–mTOR pathway and the RAS–RAF–MEK–ERK pathway. Note that mTOR
  leads to upregulation of basal levels of HIFα. Also shown within these pathways
  is a subset of the known therapeutic target sites for the monoclonal antibody to
  VEGF (bevacizumab), the tyrosine kinase inhibitors (sorafenib and sunitinib), and
  the mTOR inhibitors (temsirolimus and everolimus). AKT, protein kinase B; HIFα,
  hypoxia-inducible factor alpha; HIFβ, hypoxia-inducible factor beta; HRE, hypoxia
  response element; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol-3
  kinase.
pmcid: PMC2963106
papertitle: The role of VHL in clear-cell renal cell carcinoma and its relation to
  targeted therapy.
reftext: Peter E. Clark. Kidney Int. ;76(9):939-945.
pmc_ranked_result_index: '80094'
pathway_score: 0.9036125
filename: nihms238832f2.jpg
figtitle: VHL in clear-cell renal cell carcinoma and its relation to targeted therapy
year: ''
organisms: Homo sapiens
ndex: 3a6f8063-df13-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2963106__nihms238832f2.html
  '@type': Dataset
  description: Binding of the HIFα–HIFβ heterodimer to the HRE in the promoter region
    results in transcriptional upregulation of genes important to the cell’s response
    to hypoxia. These include vascular endothelial growth factor (VEGF), platelet-derived
    growth factor (PDGF), transforming growth factor alpha (TGFα), carbonic anhydrase
    IX (CA-IX), erythropoietin (EPO), glucose transporter 1 (GLUT-1), and BCL2/adenovirus
    E1B 19 kDa-interacting protein 3 (BNIP3). Binding of ligands, such as VEGF, to
    their respective cell surface receptors, such as VEGFR, leads to tyrosine phosphorylation
    of the receptor and subsequent downstream signaling through several kinase-dependent
    pathways, such as the PI3K–Akt–mTOR pathway and the RAS–RAF–MEK–ERK pathway. Note
    that mTOR leads to upregulation of basal levels of HIFα. Also shown within these
    pathways is a subset of the known therapeutic target sites for the monoclonal
    antibody to VEGF (bevacizumab), the tyrosine kinase inhibitors (sorafenib and
    sunitinib), and the mTOR inhibitors (temsirolimus and everolimus). AKT, protein
    kinase B; HIFα, hypoxia-inducible factor alpha; HIFβ, hypoxia-inducible factor
    beta; HRE, hypoxia response element; mTOR, mammalian target of rapamycin; PI3K,
    phosphatidylinositol-3 kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CB
  - MAPK12
  - MAP2K2
  - PIK3CA
  - HRAS
  - MAPK9
  - MAP2K1
  - MAPK13
  - EPO
  - PIK3CD
  - PIK3R5
  - PIK3R4
  - MAPK3
  - MAPK14
  - KRAS
  - MAPK10
  - NRAS
  - MTOR
  - PDGFA
  - PIK3R6
  - BRAF
  - EGFR
  - EPAS1
  - MAPK8
  - MAPK11
  - HIF3A
  - SLC2A1
  - MAPKAPK2
  - PIK3CG
  - PIK3R3
  - PDGFD
  - PDGFRA
  - PDGFRB
  - CA9
  - ARNT2
  - ARNTL
  - HIF1A
  - MAPK1
  - AKT1
  - AKT2
  - VEGFD
  - AKT3
  - KDR
  - ARAF
  - RAF1
  - MAPKAPK3
  - PDGFB
  - PDGFC
  - BNIP3
  - FLT4
  - ARNT
  - VEGFC
  - VEGFA
  - PGF
  - VEGFB
  - FLT1
  - Temsirolimus
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: EPO
  symbol: EPO
  source: hgnc_symbol
  hgnc_symbol: EPO
  entrez: '2056'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: GLUT1
  symbol: GLUT1
  source: hgnc_prev_symbol
  hgnc_symbol: SLC2A1
  entrez: '6513'
- word: MAPKAPK2/3
  symbol: MAPKAPK2
  source: hgnc_symbol
  hgnc_symbol: MAPKAPK2
  entrez: '9261'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: CA-IX
  symbol: CAIX
  source: hgnc_alias_symbol
  hgnc_symbol: CA9
  entrez: '768'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: MAPKAPK2/3
  symbol: MAPKAPK3
  source: hgnc_symbol
  hgnc_symbol: MAPKAPK3
  entrez: '7867'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: BNIP3
  symbol: BNIP3
  source: hgnc_symbol
  hgnc_symbol: BNIP3
  entrez: '664'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
